Point-counterpoint: Piperacillin-tazobactam should be used to treat infections with extended-spectrum-beta-lactamase-positive organisms

Audrey N. Schuetz, Sergio Reyes, Pranita Tamma

Research output: Contribution to journalArticle

Abstract

Points of agreement 1. The decision to use PTZ to treat an infection with an ESBL-GNR is complex and requires consideration of the source of the infection, the severity of the infection, the identity of the organism, the MIC of the organism, and the dosage of antibiotic used. 2. PTZ may be effective for treating invasive ESBL-GNR infections in patients who are not critically ill and who have a lower inoculum of infection and a lower MIC (2 g/ml). 3. The strongest data supporting the use of a BLBLI for treating infections caused by ESBL-GNR are those from urinary tract infections and possibly biliary tract infections. 4. Therapy using BLBLIs appears to be less effective than carbapenem therapy for bloodstream infections due to ESBL-GNR. 5. If PTZ is used for these infections, the laboratory should report MIC data and perform ESBL confirmatory testing to provide clinicians with optimal information for clinical decisions. 6. Laboratories that perform ESBL confirmatory testing should consider inclusion of a comment indicating that PTZ therapy may be inadequate for treating bloodstream infections or other serious infections. Points requiring further consideration 1. The efficacy of BLBLIs for bloodstream infections due to ESBL-producing organisms needs to be assessed in a large multicenter trial. The ongoing MERINO study, a randomized controlled trial of PTZ versus meropenem for the treatment of bloodstream infections due to these organisms, should provide much-needed data on appropriate treatment options. 2. Similar studies are needed for other types of infections, such as intra-abdominal infections. 3. Outcomes studies assessing the clinical utility of rapid molecular methods for detecting ESBL-producing organism are needed to assist clinical laboratories in determining the ideal approach for confirming identification of ESBL-producing organisms.

Original languageEnglish (US)
JournalJournal of Clinical Microbiology
Volume56
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

beta-Lactamases
Infection
meropenem
tazobactam drug combination piperacillin
Laboratory Infection
Intraabdominal Infections
Therapeutics
Carbapenems
Biliary Tract
Critical Illness
Urinary Tract Infections
Multicenter Studies
Randomized Controlled Trials
Outcome Assessment (Health Care)
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

@article{2a71e5eb754b4a3aa9a080d24ac0a9a2,
title = "Point-counterpoint: Piperacillin-tazobactam should be used to treat infections with extended-spectrum-beta-lactamase-positive organisms",
abstract = "Points of agreement 1. The decision to use PTZ to treat an infection with an ESBL-GNR is complex and requires consideration of the source of the infection, the severity of the infection, the identity of the organism, the MIC of the organism, and the dosage of antibiotic used. 2. PTZ may be effective for treating invasive ESBL-GNR infections in patients who are not critically ill and who have a lower inoculum of infection and a lower MIC (2 g/ml). 3. The strongest data supporting the use of a BLBLI for treating infections caused by ESBL-GNR are those from urinary tract infections and possibly biliary tract infections. 4. Therapy using BLBLIs appears to be less effective than carbapenem therapy for bloodstream infections due to ESBL-GNR. 5. If PTZ is used for these infections, the laboratory should report MIC data and perform ESBL confirmatory testing to provide clinicians with optimal information for clinical decisions. 6. Laboratories that perform ESBL confirmatory testing should consider inclusion of a comment indicating that PTZ therapy may be inadequate for treating bloodstream infections or other serious infections. Points requiring further consideration 1. The efficacy of BLBLIs for bloodstream infections due to ESBL-producing organisms needs to be assessed in a large multicenter trial. The ongoing MERINO study, a randomized controlled trial of PTZ versus meropenem for the treatment of bloodstream infections due to these organisms, should provide much-needed data on appropriate treatment options. 2. Similar studies are needed for other types of infections, such as intra-abdominal infections. 3. Outcomes studies assessing the clinical utility of rapid molecular methods for detecting ESBL-producing organism are needed to assist clinical laboratories in determining the ideal approach for confirming identification of ESBL-producing organisms.",
author = "Schuetz, {Audrey N.} and Sergio Reyes and Pranita Tamma",
year = "2018",
month = "3",
day = "1",
doi = "10.1128/JCM.01917-17",
language = "English (US)",
volume = "56",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Point-counterpoint

T2 - Piperacillin-tazobactam should be used to treat infections with extended-spectrum-beta-lactamase-positive organisms

AU - Schuetz, Audrey N.

AU - Reyes, Sergio

AU - Tamma, Pranita

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Points of agreement 1. The decision to use PTZ to treat an infection with an ESBL-GNR is complex and requires consideration of the source of the infection, the severity of the infection, the identity of the organism, the MIC of the organism, and the dosage of antibiotic used. 2. PTZ may be effective for treating invasive ESBL-GNR infections in patients who are not critically ill and who have a lower inoculum of infection and a lower MIC (2 g/ml). 3. The strongest data supporting the use of a BLBLI for treating infections caused by ESBL-GNR are those from urinary tract infections and possibly biliary tract infections. 4. Therapy using BLBLIs appears to be less effective than carbapenem therapy for bloodstream infections due to ESBL-GNR. 5. If PTZ is used for these infections, the laboratory should report MIC data and perform ESBL confirmatory testing to provide clinicians with optimal information for clinical decisions. 6. Laboratories that perform ESBL confirmatory testing should consider inclusion of a comment indicating that PTZ therapy may be inadequate for treating bloodstream infections or other serious infections. Points requiring further consideration 1. The efficacy of BLBLIs for bloodstream infections due to ESBL-producing organisms needs to be assessed in a large multicenter trial. The ongoing MERINO study, a randomized controlled trial of PTZ versus meropenem for the treatment of bloodstream infections due to these organisms, should provide much-needed data on appropriate treatment options. 2. Similar studies are needed for other types of infections, such as intra-abdominal infections. 3. Outcomes studies assessing the clinical utility of rapid molecular methods for detecting ESBL-producing organism are needed to assist clinical laboratories in determining the ideal approach for confirming identification of ESBL-producing organisms.

AB - Points of agreement 1. The decision to use PTZ to treat an infection with an ESBL-GNR is complex and requires consideration of the source of the infection, the severity of the infection, the identity of the organism, the MIC of the organism, and the dosage of antibiotic used. 2. PTZ may be effective for treating invasive ESBL-GNR infections in patients who are not critically ill and who have a lower inoculum of infection and a lower MIC (2 g/ml). 3. The strongest data supporting the use of a BLBLI for treating infections caused by ESBL-GNR are those from urinary tract infections and possibly biliary tract infections. 4. Therapy using BLBLIs appears to be less effective than carbapenem therapy for bloodstream infections due to ESBL-GNR. 5. If PTZ is used for these infections, the laboratory should report MIC data and perform ESBL confirmatory testing to provide clinicians with optimal information for clinical decisions. 6. Laboratories that perform ESBL confirmatory testing should consider inclusion of a comment indicating that PTZ therapy may be inadequate for treating bloodstream infections or other serious infections. Points requiring further consideration 1. The efficacy of BLBLIs for bloodstream infections due to ESBL-producing organisms needs to be assessed in a large multicenter trial. The ongoing MERINO study, a randomized controlled trial of PTZ versus meropenem for the treatment of bloodstream infections due to these organisms, should provide much-needed data on appropriate treatment options. 2. Similar studies are needed for other types of infections, such as intra-abdominal infections. 3. Outcomes studies assessing the clinical utility of rapid molecular methods for detecting ESBL-producing organism are needed to assist clinical laboratories in determining the ideal approach for confirming identification of ESBL-producing organisms.

UR - http://www.scopus.com/inward/record.url?scp=85042606161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042606161&partnerID=8YFLogxK

U2 - 10.1128/JCM.01917-17

DO - 10.1128/JCM.01917-17

M3 - Article

C2 - 29237787

AN - SCOPUS:85042606161

VL - 56

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 3

ER -